Merck & Co. May 16, 2026 Merck & Co., Inc. stock (US58933Y1055): Keytruda momentum and fresh earnings keep big pharma in focu - AD HOC NEWS
Merck & Co. May 15, 2026 Merck & Co., Inc. stock (US58933Y1055): pharma giant doubles down on M&A as investors eye post-Keytr - AD HOC NEWS
Merck & Co. May 14, 2026 AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda - Fierce Pharma
Merck & Co. May 14, 2026 Merck & Co., Inc. stock (US58933Y1055): Latest developments and business overview - AD HOC NEWS
Merck & Co. May 13, 2026 Cortisone Shots Market 2026 | Merck & Co, Pfizer, Bristol-Myers Squibb, Novartis, Pharmascience etc. - openPR.com
Merck & Co. May 12, 2026 Merck & Co. stock (US58933Y1055): Oncology portfolio advances at ASCO 2026 - AD HOC NEWS
Merck & Co. May 12, 2026 Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma - The Manila Times
Merck & Co. May 12, 2026 Erasca partners with Merck on best-in-class pan-RAS molecular glue - The Pharma Letter
Merck & Co. May 11, 2026 Pharma ETFs: Your Key to Diversification in the Pharmaceutical Sector - Investing News Network
Merck & Co. May 11, 2026 Merck makes a new move in Astra battle | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Merck & Co. May 11, 2026 Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data - Fierce Biotech
Merck & Co. May 9, 2026 Merck & Co. Inc. stock (US58933Y1055): Earnings beat and pipeline update drive investor interest - AD HOC NEWS
Merck & Co. May 7, 2026 Merck & Co Completes $5.3-Bn Acquisition of Terns Pharmaceuticals - DCAT Value Chain Insights
Merck & Co. May 7, 2026 From drug development to M&A, Big Pharmas showcase AI’s ‘measurable impact’ - Fierce Biotech
Merck & Co. May 6, 2026 Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees - Business Wire
Merck & Co. May 1, 2026 Merck quietly ditches its sac-tmt copy | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Merck & Co. May 1, 2026 Spotlight On: Merck & Co. maintains BD appetite ahead of $70B sales goal - FirstWord Pharma
Merck & Co. Apr 30, 2026 Merck & Co.'s Keytruda posts $8B in Q1 as Qlex picks up steam - FirstWord Pharma